Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Monte Rosa Therapeutics Inc banner
M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 17.815 USD -3.7% Market Closed
Market Cap: $1.3B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

GLUE Price Targets Summary
Monte Rosa Therapeutics Inc

Wall Street analysts forecast GLUE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLUE is 29.871 USD with a low forecast of 17.17 USD and a high forecast of 38.85 USD.

GLUE Lowest Forecast
Wall Street Target
17.17 USD
-4% Downside
GLUE Average Forecast
Wall Street Target
29.871 USD
68% Upside
GLUE Highest Forecast
Wall Street Target
38.85 USD
118% Upside
Lowest
Price Target
17.17 USD
4% Downside
Average
Price Target
29.871 USD
68% Upside
Highest
Price Target
38.85 USD
118% Upside
Monte Rosa Therapeutics Inc Competitors:
Price Targets
VINP
Vinci Partners Investments Ltd
16% Upside
CDNA
CareDx Inc
29% Upside
B
BRI
Britania PCL
-1% Downside
ACAD
ACADIA Pharmaceuticals Inc
32% Upside
VINP
Vinci Partners Investments Ltd
16% Upside
CDNA
CareDx Inc
29% Upside
B
BRI
Britania PCL
-1% Downside
ACAD
ACADIA Pharmaceuticals Inc
32% Upside
CIGI
Colliers International Group Inc
11% Upside

Revenue
Forecast

N/A
Past Growth
-11% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
-11% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Monte Rosa Therapeutics Inc's revenue for the next 4 years is -11%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-36%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-36%
Average Miss

What are analyst estimates?

See Also

Summary
GLUE intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLUE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLUE stock valuation using valuation multiples.
Wall Street Estimates
GLUE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLUE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GLUE's stock price target?
Price Target
29.871 USD

According to Wall Street analysts, the average 1-year price target for GLUE is 29.871 USD with a low forecast of 17.17 USD and a high forecast of 38.85 USD.

What is Monte Rosa Therapeutics Inc's Revenue forecast?
Projected CAGR
-11%

The compound annual growth rate of Monte Rosa Therapeutics Inc's revenue for the next 4 years is -11%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 321,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett